Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Hold at Zacks Investment Research
According to Zacks, “Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. “
Several other research firms have also issued reports on SGMO. BidaskClub raised shares of Sangamo Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, October 30th. Wedbush reissued a hold rating and issued a $11.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, November 12th. ValuEngine raised shares of Sangamo Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Finally, HC Wainwright initiated coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They issued a buy rating and a $16.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $13.50.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative net margin of 159.12% and a negative return on equity of 30.33%. The firm had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. During the same quarter in the prior year, the business posted ($0.13) earnings per share. The company’s quarterly revenue was down 6.8% compared to the same quarter last year. On average, equities analysts anticipate that Sangamo Therapeutics will post -1.21 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. First Manhattan Co. acquired a new stake in shares of Sangamo Therapeutics during the second quarter worth approximately $32,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Sangamo Therapeutics during the second quarter worth approximately $50,000. Tiverton Asset Management LLC acquired a new stake in shares of Sangamo Therapeutics during the second quarter worth approximately $79,000. Tower Research Capital LLC TRC increased its holdings in shares of Sangamo Therapeutics by 1,621.1% during the third quarter. Tower Research Capital LLC TRC now owns 11,170 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 10,521 shares in the last quarter. Finally, McGuire Investment Group LLC acquired a new stake in shares of Sangamo Therapeutics during the third quarter worth approximately $110,000. 70.63% of the stock is owned by institutional investors.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Story: Trading based on a resistance level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.